drugset
drugset / Trial / NCT01281163

Lapatinib Ditosylate and Akt Inhibitor MK2206 in Treating Women With Metastatic Breast Cancer

NCT01281163 ↗

Phase 1 Terminated 4 enrolled National Cancer Institute (NCI)
NaSingle-groupOpen-labelTreatment

Summary

This phase I trial studies the side effects and the best dose of lapatinib ditosylate and Akt inhibitor MK2206 in treating women with metastatic breast cancer. Lapatinib ditosylate and Akt inhibitor MK2206 may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth.

Timeline

Start
2011-01
Primary completion
2013-12
Completion
2013-12

Drugs

EvaluationDrugModalityDoseRoute
Subject Lapatinib Small molecule — Oral
Subject MK-2206 Small molecule — Oral

Indications

HER2 positive breast carcinoma estrogen-receptor negative breast cancer estrogen-receptor positive breast cancer progesterone-receptor negative breast cancer progesterone-receptor positive breast cancer